Compugen Announces In Vivo Confirmation of Cardiovascular Therapeutic Potential for Two Novel Peptides
14 Mayo 2009 - 6:00AM
Business Wire
Compugen Ltd. (NASDAQ:CGEN) announced today follow-on positive
in-vivo results for CGEN-856 and CGEN-857, two novel peptide
agonists of the MAS G-protein coupled receptor (GPCR), the
discovery of which was disclosed by the Company last year. These
results, obtained from a series of recently completed studies,
demonstrate both the cardioprotective and anti-hypertensive effects
of these two product candidates.
In an animal model of myocardial infarction, both CGEN-856 and
CGEN-857 afforded cardioprotection, as manifested by reduction of
infarct size and cardiac function. This effect was similar to that
obtained with Captopril, a known ACE inhibitor drug. In another
study, acute administration of CGEN-856 to normotensive or
hypertensive rats resulted in a dose-dependent decrease in blood
pressure, which was significantly more pronounced in the
hypertensive rats. The anti-hypertensive effect of CGEN-856 was
maintained for more than one hour post infusion, suggesting that
its in-vivo stability is higher than that of Ang(1-7), the known
ligand of the MAS receptor.
CGEN-856 and CGEN-857 were predicted and selected in silico
through the use of the Company�s GPCR peptide ligand discovery
platform, following which initial validation studies indicated
potential vasodilating, anti-arrhythmogenic and cardioprotective
effects. The results of the recent studies being reported today
provide further confirmation that CGEN-856 and CGEN-857 have the
potential to be developed as cardioprotective and anti-hypertensive
therapeutic agents.
Compugen vice president for R&D Dr. Anat Cohen Dayag said,
�All of our product candidates, including CGEN-856 and 857, begin
purely as computer generated theoretical predictions. Thus we are
extremely pleased by the rapidly growing amount of experimental
validation supporting the validity of our in silico predictions,
both in terms of breadth of applications and depth of confirmation.
This increasing body of evidence not only validates the specific
platforms and products involved, but more importantly demonstrates
the commercial potential resulting from our very successful decade
long research focus on gaining predictive understandings of key
physiological processes at the molecular level.�
About MAS GPCR and the Renin-Angiotensin System
The MAS GPCR is a component of the renin-angiotensin system
(RAS), which is considered to be one of the most important
regulatory systems for cardiovascular health. The RAS, which was
originally considered to be a linear system, is now known to have
two major counter-regulatory arms. The first and well studied arm
is the ACE-angiotensin II axis, and existing drugs that inhibit
RAS. These include ACE inhibitors and angiotensin II receptor
blockers (ARBs). The more recently discovered counter regulatory
arm is the ACE2 � angiotensin(1-7)-MAS axis, which includes the MAS
receptor which CGEN-856 and CGEN-857 have been shown to activate.
Recent studies indicate that activation of the MAS axis exerts
cardioprotective effects, including prevention of detrimental
cardiac remodeling following ischemia, improvement of cardiac
function, attenuation of renal abnormalities associated with
hypertension and reduction of the duration of cardiac arrhythmias
in response to reperfusion injury, thus pointing to this axis as a
potential target for cardiovascular drug development.
About Compugen
Compugen is a leading drug and diagnostic product candidate
discovery company. Unlike traditional high throughput trial and
error experimental based discovery, Compugen�s discovery efforts
are based on in-silico (by computer) prediction and selection
utilizing a growing number of field focused proprietary discovery
platforms accurately modeling biological processes at the molecular
level. The resulting product candidates are then validated through
in vitro and in vivo experimental studies and out-licensed for
further development and commercialization under various forms of
revenue sharing agreements. Compugen�s current collaborations
include Biosite, Medarex, Inc., Merck & Co., Inc., Merck
Serono, Ortho-Clinical Diagnostics (a Johnson & Johnson
company), Roche, Siemens Healthcare Diagnostics, Inc., and Teva
Pharmaceutical Industries. In 2002, Compugen established an
affiliate, Evogene Ltd. www.evogene.com (TASE: EVGN.TA), to utilize
certain of the Company�s in-silico predictive discovery
capabilities in agricultural biotechnology. For additional
information, please visit Compugen's corporate Web site at
www.cgen.com.
This press release may contain "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. These statements include words such as �may�, �expects�,
�anticipates�, �believes�, and �intends�, and describe opinions
about future events. These forward-looking statements involve known
and unknown risks and uncertainties that may cause the actual
results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Some of
these risks are: changes in relationships with collaborators; the
impact of competitive products and technological changes; risks
relating to the development of new products; and the ability to
implement technological improvements. These and other factors are
identified and more fully explained under the heading "Risk
Factors" in Compugen's annual reports filed with the Securities and
Exchange Commission.
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Compugen (NASDAQ:CGEN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024